Cargando…
Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches
Antiplatelet agents, with aspirin and P2Y(12) receptor antagonists as major key molecules, are currently the cornerstone of pharmacological treatment of atherothrombotic events including a variety of cardio- and cerebro-vascular as well as peripheral artery diseases. Over the last decades, significa...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832164/ https://www.ncbi.nlm.nih.gov/pubmed/35155631 http://dx.doi.org/10.3389/fcvm.2022.805525 |
_version_ | 1784648667477573632 |
---|---|
author | Jourdi, Georges Godier, Anne Lordkipanidzé, Marie Marquis-Gravel, Guillaume Gaussem, Pascale |
author_facet | Jourdi, Georges Godier, Anne Lordkipanidzé, Marie Marquis-Gravel, Guillaume Gaussem, Pascale |
author_sort | Jourdi, Georges |
collection | PubMed |
description | Antiplatelet agents, with aspirin and P2Y(12) receptor antagonists as major key molecules, are currently the cornerstone of pharmacological treatment of atherothrombotic events including a variety of cardio- and cerebro-vascular as well as peripheral artery diseases. Over the last decades, significant changes have been made to antiplatelet therapeutic and prophylactic strategies. The shift from a population-based approach to patient-centered precision medicine requires greater awareness of individual risks and benefits associated with the different antiplatelet strategies, so that the right patient gets the right therapy at the right time. In this review, we present the currently available antiplatelet agents, outline different management strategies, particularly in case of bleeding or in perioperative setting, and develop the concept of high on-treatment platelet reactivity and the steps toward person-centered precision medicine aiming to optimize patient care. |
format | Online Article Text |
id | pubmed-8832164 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88321642022-02-12 Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches Jourdi, Georges Godier, Anne Lordkipanidzé, Marie Marquis-Gravel, Guillaume Gaussem, Pascale Front Cardiovasc Med Cardiovascular Medicine Antiplatelet agents, with aspirin and P2Y(12) receptor antagonists as major key molecules, are currently the cornerstone of pharmacological treatment of atherothrombotic events including a variety of cardio- and cerebro-vascular as well as peripheral artery diseases. Over the last decades, significant changes have been made to antiplatelet therapeutic and prophylactic strategies. The shift from a population-based approach to patient-centered precision medicine requires greater awareness of individual risks and benefits associated with the different antiplatelet strategies, so that the right patient gets the right therapy at the right time. In this review, we present the currently available antiplatelet agents, outline different management strategies, particularly in case of bleeding or in perioperative setting, and develop the concept of high on-treatment platelet reactivity and the steps toward person-centered precision medicine aiming to optimize patient care. Frontiers Media S.A. 2022-01-28 /pmc/articles/PMC8832164/ /pubmed/35155631 http://dx.doi.org/10.3389/fcvm.2022.805525 Text en Copyright © 2022 Jourdi, Godier, Lordkipanidzé, Marquis-Gravel and Gaussem. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Jourdi, Georges Godier, Anne Lordkipanidzé, Marie Marquis-Gravel, Guillaume Gaussem, Pascale Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches |
title | Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches |
title_full | Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches |
title_fullStr | Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches |
title_full_unstemmed | Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches |
title_short | Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches |
title_sort | antiplatelet therapy for atherothrombotic disease in 2022—from population to patient-centered approaches |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832164/ https://www.ncbi.nlm.nih.gov/pubmed/35155631 http://dx.doi.org/10.3389/fcvm.2022.805525 |
work_keys_str_mv | AT jourdigeorges antiplatelettherapyforatherothromboticdiseasein2022frompopulationtopatientcenteredapproaches AT godieranne antiplatelettherapyforatherothromboticdiseasein2022frompopulationtopatientcenteredapproaches AT lordkipanidzemarie antiplatelettherapyforatherothromboticdiseasein2022frompopulationtopatientcenteredapproaches AT marquisgravelguillaume antiplatelettherapyforatherothromboticdiseasein2022frompopulationtopatientcenteredapproaches AT gaussempascale antiplatelettherapyforatherothromboticdiseasein2022frompopulationtopatientcenteredapproaches |